Rotavirus, Live Attenuated
drugOn this page
Also known as RotarixRotashieldRotaviruslive attenuated
Summary
Rotavirus, Live Attenuated (CHEMBL6068351) is an approved vaccine component; indicated across 2 conditions including rotavirus infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Vaccine component
- Indications: 2 conditions
- Clinical trials: 35
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL6068351 |
| Name | Rotavirus, Live Attenuated |
| Type | Vaccine component |
| Max phase | 4 |
Also known as: Rotarix, Rotashield, Rotavirus, live attenuated, ROTAVIRUS, LIVE ATTENUATED
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| Rotavirus infection | 4 | MONDO:0005194 | EFO:0002622 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 35.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 19 |
| PHASE4 | 8 |
| PHASE2 | 6 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02941107 | PHASE4 | ACTIVE_NOT_RECRUITING | Optimising Rotavirus Vaccine in Aboriginal Children |
| NCT00995813 | PHASE4 | COMPLETED | Pilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure |
| NCT01700621 | PHASE4 | COMPLETED | Coadministration of Measles-rubella and Rotavirus Vaccines |
| NCT01841671 | PHASE4 | UNKNOWN | Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine |
| NCT02847026 | PHASE4 | COMPLETED | Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study |
| NCT02907216 | PHASE4 | COMPLETED | Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals’ Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants |
| NCT02992197 | PHASE4 | COMPLETED | The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity |
| NCT03587389 | PHASE4 | COMPLETED | Response to Rotavirus Vaccine in Infants in Ho Chi Minh City in Vietnam |
| NCT06824181 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age |
| NCT06824194 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age |
| NCT00370318 | PHASE3 | COMPLETED | Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines |
| NCT00396630 | PHASE3 | COMPLETED | A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family. |
| NCT00480324 | PHASE3 | COMPLETED | Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants |
| NCT00489554 | PHASE3 | COMPLETED | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age |
| NCT00533507 | PHASE3 | COMPLETED | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age |
| NCT00757770 | PHASE3 | COMPLETED | Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals’ HRV Vaccine |
| NCT00808444 | PHASE3 | COMPLETED | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age |
| NCT00829010 | PHASE3 | COMPLETED | Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age. |
| NCT01375647 | PHASE3 | COMPLETED | Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh |
| NCT01983540 | PHASE3 | COMPLETED | Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination |
| NCT02096263 | PHASE3 | COMPLETED | Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants |
| NCT02193061 | PHASE3 | COMPLETED | Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs |
| NCT02584816 | PHASE3 | COMPLETED | Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization |
| NCT02914184 | PHASE3 | COMPLETED | Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals’ Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks |
| NCT03207750 | PHASE3 | COMPLETED | This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals’ Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK’s Licensed Lyophilized Vaccine |
| NCT03621670 | PHASE3 | COMPLETED | Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants |
| NCT04010448 | PHASE3 | UNKNOWN | A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India |
| NCT00263666 | PHASE2 | COMPLETED | A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa |
| NCT00425737 | PHASE2 | COMPLETED | Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants |
| NCT00429481 | PHASE2 | COMPLETED | Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants |
| NCT01377571 | PHASE2 | COMPLETED | A Dose-escalating Study to Evaluate the Immunogenicity and Safety of Rotavin-M1 Vaccine in Healthy Infants |
| NCT04344054 | PHASE2 | COMPLETED | Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine |
| NCT04658914 | PHASE2 | COMPLETED | Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa |
| NCT03507738 | PHASE1 | COMPLETED | Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants |
| NCT00353366 | Not specified | COMPLETED | To Evaluate Safety & Reactogenicity of GSK Bio’s Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: Rotavirus infection